$STX

Teh Ban Seng sold $871K of STX

Teh Ban Seng (EVP & Chief Commercial Officer) sold 989 shares of Seagate Technology Holdings plc (STX) at $880.19 ($0.87M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Teh Ban Seng
Published Jun 15, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
high confidence
Mentioned
$STX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

The disclosure confirms an officer’s pre-arranged open-market sale; without accompanying fundamental news, it is unlikely to drive repricing by itself.

02

Market read

Traders may note insider selling, but the pre-arranged nature and lack of new fundamentals make it low-impact.

03

What to watch

The article provides only one sale size and does not indicate whether other insiders are selling/buying, nor any change in company outlook.

Relevance 4/10Novelty 2/10Timing: SEC Form 4 filed 2026-06-15 for a 2026-06-12 insider sale

Background

The filing is an SEC Form 4 insider transaction for Seagate Technology Holdings plc (STX).

Company-level read

Ticker impact

$STXNeutralHigh confidence
Context

Seagate executive Teh Ban Seng sold $870,507 of STX shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other catalysts.

Evidence & confidence

Form 4 discloses a small, pre-planned sale by an officer; it is not a buy, not tied to new fundamentals, and provides no guidance or operational change.

Market effects

No sector-level read-through; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private views; traders may watch for clustering of insider sales around other negative signals.

Key entities

  • Seagate Technology Holdings plc

    STX insider transaction disclosed via SEC Form 4.

  • Teh Ban Seng

    EVP & Chief Commercial Officer who sold 989 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.